Landscape Capital Management L.L.C. Purchases Shares of 169,531 Haleon plc (NYSE:HLN)

Landscape Capital Management L.L.C. acquired a new position in Haleon plc (NYSE:HLN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 169,531 shares of the company’s stock, valued at approximately $1,794,000.

Other institutional investors also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in Haleon in the third quarter worth $28,000. Cultivar Capital Inc. purchased a new stake in Haleon during the 2nd quarter valued at about $40,000. Prospera Private Wealth LLC purchased a new stake in Haleon during the 3rd quarter valued at about $57,000. Hexagon Capital Partners LLC grew its position in Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after acquiring an additional 2,677 shares during the last quarter. Finally, BOKF NA increased its stake in Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 0.8 %

Shares of Haleon stock opened at $9.56 on Friday. The company’s fifty day simple moving average is $10.03 and its two-hundred day simple moving average is $9.37. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market cap of $43.25 billion, a P/E ratio of 28.10, a PEG ratio of 2.86 and a beta of 0.30.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank initiated coverage on shares of Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. Morgan Stanley increased their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.